Adaptimmune Therapeutics PLC cotiza a 0.03 USD y tiene una capitalización bursátil de $8M. En los últimos 12 meses ha facturado $65M con un margen de flujo de caja libre del -41.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
| Periodo | 2026-04 | 2025-08 | 2025-05 | 2025-03 |
|---|---|---|---|---|
| Real | — | $-0.12 | $-0.18 | $-0.30 |
| Estimado | $-0.12 | $-0.13 | $-0.16 | $-0.13 |
| Sorpresa | — | +7.7% | -12.5% | -130.8% |
| Métrica | ADAPY | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 100.0% | 57.0% | +42.9% |
| Operating Margin | -38.6% | -38.6% | 0.0% |
| Net Margin | -39.8% | -33.6% | -6.2% |
| FCF Margin | -41.6% | -13.9% | -27.8% |
| ROE | -597.6% | -40.4% | -557.2% |
| ROA | -28.8% | -32.0% | +3.2% |
| Current Ratio | 2.92 | 2.84 | +0.08 |
| Debt / Equity | 4.58 | 0.28 | +4.30 |